Intravenous drug therapy provider Infusion Express (IVX) has raised $13.5 million of growth capital in a round led by McKesson Ventures and Health Velocity Capital, with additional support from Nueterra Capital. Infusion Express will use the money to expand its services to chronically ill patients, insurance payers, and self-insured employers.
“Infusion Express’ mission from the outset has been to create a superior experience for those patients with chronic conditions such as ALS, MS, Crohn’s Disease, rheumatoid arthritis, other autoimmune disorders, and primary immune deficiencies,” said Don Peterson, Founder and CEO of Infusion Express. “Our success in Kansas City and in our first wave of expansion has encouraged us to bring our services to other communities across the U.S. This funding and the strategic value of these investors will enable us to further that mission.”
“As patients continue to redefine how and where they seek care, the Infusion Express model stands out as a leader in delivering a high quality patient experience, said McKesson Ventures’ Managing Director, Dave Schulte. “And that experience enables higher adherence to therapy which leads to better outcomes and a growing network of satisfied patients and providers.”
“Health Velocity Capital is excited to partner with Infusion Express to increase convenient access to IV therapy for patients with chronic conditions,” said Bruce Crosby, Managing Partner at Health Velocity Capital. “Infusion Express’ consumer friendly model provides patients with a comfortable, private setting, high clinical quality, and lower costs. The company’s rapid growth is due to favorable consumer word-of-mouth and strong physician endorsement.”
Inc. Magazine recently named Infusion Express the 60th fastest growing company in America, and the Kansas City Business Journal deemed it the 3rd fastest growing company in Kansas City.
Learn more about Infusion Express’s recent growth in this exclusive Kansas City Business Journal article.